Mepolizumab and the treatment of chronic rhinosinusitis

from The Lancet Respiratory Medicine in conversation with · host The Lancet Respiratory Medicine

Dr. Joseph Han discusses the results of the phase III SYNAPSE trial, evaluating the efficacy and safety of mepolizumab in patients with chronic rhinosinusitis. Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00097-7/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Episode metadata supplied by the publisher feed · Published Apr 16, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

Mepolizumab and the treatment of chronic rhinosinusitis

0:00 7:18

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Lancet Respiratory Medicine in conversation with?

This episode is 7 minutes long.

When was this The Lancet Respiratory Medicine in conversation with episode published?

This episode was published on April 16, 2021.

Can I download this The Lancet Respiratory Medicine in conversation with episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!